Healthy volunteers test new reversal agent in Early-Stage trial
NCT ID NCT07202663
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 23 times
Summary
This early-stage study tested the safety of a new drug called BB-025 in 72 healthy adults. Some participants received BB-025 alone, while others got it after another drug, BB-031. The goal was to see if BB-025 is safe and how the body processes it, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Scintia Clinical Research Ltd
Randwick, New South Wales, Australia
Conditions
Explore the condition pages connected to this study.